The presence of a patent foramen ovale (PFO) has been associated with an increase incidence of cryptogenic stroke. Patients who have a PFO and an associated thrombophilia may have an increased risk of cerebral ischemic events. Percutaneous PFO closure could be a safe and effective alternative therapeutic approach for these patients. Methods: Consecutive patients who underwent PFO closure at a large academic centre were evaluated. All patients underwent hypercoagulation testing with functional assays for homocysteine; proteins C and S; antithrombin III; factor II mutation; factor V-Leiden mutation; lipoprotein (a); elevated levels of antiphospholipids; including lupus anticoagulant (LAC), anticardiolipin (aCL). We compared the safety and efficacy of percutaneous PFO closure in this group of patients versus the group of patients without a hypercoagulable state. Results: Of 728 consecutive patients with PFO undergoing percutaneous PFO closure, a hypercoagulable state was found in 234 patients (32.1%). There were no significant differences on baseline demographics or echocardiographic characteristics. There were no differences on success rate and complication rate between both groups. Follow up was available in 708 patients (97.3%). Median follow-up was 17 month. During follow-up there were no differences in TIA/stroke incidence (0.4% in the group with coagulation disorder and 0.6% in the non-hypercoagulable group, log rank test p ϭ0.997).
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Results of the Amplatzer Cardiac Plug European Multicenter Prospective Observational Study
University of Madrid, Madrid, Spain, 14 Royal Sussex County Hospital, Brighton, United Kingdom, 15 Hospital de Navarra, Pamplona, Spain Background: Many patients with atrial fibrillation (AF) at high risk for thromboembolic events are not candidates for long-term oral anticoagulation (OAC). The left atrial appendage (LAA) is the major site of thrombus formation in non-valvular AF. We report procedural results with 6 month follow-up for LAA occlusion with the AMPLATZER™ Cardiac Plug (ACP) (St. Jude Medical, Plymouth, MN). Methods: A total of 197 patients underwent ACP implantation at one of 15 investigative centers in Europe in 2009-2011. 183 patients have completed their 6 month follow up visit. Study follow up requirements included echocardiographic assessment at baseline, pre-discharge 1 and 6 months post implant as well as rigorous neurological exam after a suspected stroke, TIA or systemic embolism. Results: The majority of patients (57.9%) had a history of permanent AF, mean age was 74.20 Ϯ 9.0, mean CHADS2 score 2.6 Ϯ 1.3. Prior stroke or TIA was reported by 39.2% of patients. Patients were indicated for ACP therapy due to bleeding risk on oral anticoagulation (OAC) (79.8%), prior hemorrhage (8.9%) or prior stroke on Warfarin (11.3%). Only 3.9% of patients were on active OAC prior to implant. The ACP device was successfully implanted in 96.6% of patients with a closure rate of 99.5% at implant and 98.9% at six months. Device/procedure related safety events included: 0 (0.0%) periprocedural strokes, 3 (1.5%) serious pericardial effusions, 5 (2.4%) device related thrombus, and 3 (1.5%) device embolizations. The stroke rate was 1.98% at 101 patient years compared with a CHADS2 prediction of 5.6%. Conclusions: Although warfarin has been shown to be effective for AF, many patients with AF are contraindicated for it. The ACP device is a good alternative for these patients based on the reported excellent implant success, LAA closure, and yields an acceptable safety profile. The rate of adverse events compares favorably with other LAA closure devices despite the high risk patients enrolled in the Study. Background: Surgical treatment of functional mitral regurgitation (FMR) in the setting of heart failure has adequate short-term results however, late recurrence of mitral regurgitation is frequent and associated with high mortality. Patients with dilated left ventricles (LV) at baseline appear to be a higher risk for early mortality (17.9%) and readmission (Braun et al., 2008) . We sought to determine the outcomes of patients with FMR and dilated ventricles treated with the MitraClip device. Methods: Prospective data was collected on patients undergoing therapy with the MitraClip at the Montreal Heart Institute and Cedars Sinai Medical Center. Echo data was obtained pre-and post-procedure. Severity of MR was assessed echocardiographically in accordance with ASE Guidelines. Procedural success was defined as residual MR grade of 2ϩ or less. Dilated left ventricle was defined as a left ventricular end-diastolic dimension (LVEDD) Ն65mm. Mortality and hospital re-admission data was obtained from chart review and hospital administration databases. Results: A total of 70 patients underwent transcatheter leaflet repair with the MitraClip at both centers during the study period. Ten were identified as having a dilated left ventricle and significant mitral regurgitation. Procedural success in this group of patients was 80% (nϭ8). In one patient, we were unable to grasp the leaflets and no clip was deployed, the patient subsequently died 12 days later from progressive renal failure while a second patient required mitral valve surgery for persistent severe MR. There were no procedural complications.
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